Dossier assessment
Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more HER2-targeted therapies
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-02-02 A G-BA decision was published.
Project details
- Project no.
- A22-81
- Commission
- Commission awarded on 29.07.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Addendum to Commission A22-81
Status: Commission completed
-
Dossier assessment
Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Trastuzumab deruxtecan (gastric cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed